Physician profile
Barry N Wasserman
NPI 1659378248
$1,406.91
in general payments reported to CMS, 2019-2025
23 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.02 · 2020: $88.11 · 2021: $412 · 2022: $440 · 2023: $77.31 · 2024: $125 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.17 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $317.23 | 2019-2024 | Wavelight Refractive Suite, Wavelight |
| Biotissue Holdings INC. | $147.65 | 2021-2022 | |
| Glaukos Corporation | $127.35 | 2025 | |
| Allergan, INC. | $119.00 | 2021-2022 | |
| Alimera Sciences, INC. | $95.49 | 2020-2021 | |
| Harrow Eye, LLC | $75.88 | 2024-2025 | Iheezo |
| Kala Pharmaceuticals, INC. | $73.00 | 2020-2022 | |
| Oyster Point Pharma, INC. | $70.31 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $44.55 | 2021-2024 | |
| Cardinal Health 108 LLC | $42.14 | 2025 | |
| Novartis Pharmaceuticals Corporation | $39.39 | 2021 | |
| Iridex Corporation | $38.56 | 2022 | |
| Dompe US, INC. | $30.61 | 2022 | |
| Mallinckrodt Hospital Products INC. | $28.45 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $28.35 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $28.08 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $19.71 | 2025 | Xdemvy |
| Rxsight INC | $18.62 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Apellis Pharmaceuticals, INC. | $18.32 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Abbvie INC. | $14.11 | 2022 | |
| Beaver-Visitec International, INC. | $12.27 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$75,054.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.